{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-008178","form_type":"8-K","ticker":"ATAI","cik":"0002081043","company_name":"AtaiBeckley Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.204393+00:00","generated_at":"2026-05-15T19:06:32.899091+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026","bullets":["Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.","Net loss $544.8M in Q4, $660M full year; includes $530M non-cash IP R&D charge from Beckley Psytech combo.","BPL-003 Phase 3 pivotal program (ReConnection-1 and -2) initiation on track for Q2 2026; topline data early 2029.","EMP-01 Phase 2a met primary safety; showed 11.85-point LSAS reduction vs placebo (p=0.036).","VLS-01 Phase 2 Elumina topline data readout anticipated H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-008178","json":"https://secwatch.observer/filing/0001140361-26-008178.json","markdown":"https://secwatch.observer/filing/0001140361-26-008178.md","text":"https://secwatch.observer/filing/0001140361-26-008178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/0001140361-26-008178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/ef20066741_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:06:32.899091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aabf75a334d287bf7a39389af9c13b98ed5ece32","claim":"AtaiBeckley Inc. reported financial results for fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 6, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate and clinical update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/0001140361-26-008178-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}